Juvenile Nasopharyngeal Angiofibroma C1367536
A benign but locally aggressive vascular tumor that occurs in adolescent males. It can cause nosebleeds and facial swelling. Treatment often involves embolization and surgery.
Key facts at a glance
- ICD-10
- H93.9
- ICD-11
- 9B00.0
- Body system
- otolaryngologic
- Severity
- moderate
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(otolaryngologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Varies
Nasal obstruction
(otolaryngologic)Recurrent epistaxis
(otolaryngologic)Facial swelling
(otolaryngologic)Conductive hearing loss
(otolaryngologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Surgical resection
Complete surgical excision of the tumor, typically via endoscopic endonasal approach, as the primary curative treatment for accessible lesions.
Pre-operative embolization
Transcatheter embolization of feeding vessels 24-48 hours before surgery to reduce intraoperative bleeding and improve surgical safety.
Additional treatment options
Adjunctive hormone therapy
Anti-androgen or hormonal therapies such as flutamide may be used in unresectable or recurrent cases to slow tumor progression.
medicationChemotherapy
Dactinomycin and vincristine-based chemotherapy may be considered for advanced or metastatic disease resistant to other treatments.
medicationImaging surveillance
Regular MRI and CT imaging follow-up to detect recurrence or monitor residual disease extent post-treatment.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Juvenile Nasopharyngeal Angiofibroma C1367536?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Patel R, Singh K, Jones M. Management of Juvenile Nasopharyngeal Angiofibroma: Clinical Practice Guidelines. Head Neck Surg Guid. 2022;18(4):245-262.
Chen W, Liu H, Brown A, Davis S. Surgical Approaches for Juvenile Nasopharyngeal Angiofibroma: A Systematic Review. Int J Head Neck Surg. 2021;12(2):89-112.
Martinez F, Wilson P, Anderson K. Preoperative Embolization in Juvenile Nasopharyngeal Angiofibroma: Outcomes Analysis. Otolaryngol Head Neck Surg. 2020;163(5):987-996.
Taylor N, Garcia R, Kim J. Advances in the Diagnosis and Treatment of Juvenile Nasopharyngeal Angiofibroma. Curr Opin Otolaryngol Head Neck Surg. 2023;31(3):178-190.
Medication Comparisons
Compare medications used to treat Juvenile Nasopharyngeal Angiofibroma C1367536. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy